A world of possibilities
Navigating life sciences and medtech to the extraordinary—driven by creativity, curiosity, and the courage to build a fulfilling journey.
-
Composition for inhalation (Osimertinib)
AstraZeneca secured strong patent protection extending into the 2030s for osimertinib and its clinical uses, including dosing and formulations that support its therapeutic effectiveness in non‑small cell lung cancer (NSCLC). Patent assets around this drug…
-
RNA-Programmable Endonuclease Systems and Uses Thereof
Patent Number: U.S. 12203110 B2Assignees: CRISPR Therapeutics AG and Bayer Healthcare LLC What This Patent Covers This patent protects novel synthetic RNA-guided endonucleases (sRGNs) — engineered CRISPR-type enzymes that can be programmed by a guide…
-
Lipid Nanoparticle (LNP) Compositions for mRNA Delivery
US 10,703,789 B2 Filing date: June 12, 2019Patent granted: July 7, 2020Assignee: ModernaTX, Inc. (Moderna) What This Patent Covers This patent claims specific lipid nanoparticle (LNP) formulations that encapsulate modified messenger RNA (mRNA) for use…
BioTech IP Review 